Trial Profile

Real World Evidence of Long-term Safety and Efficacy in Patients Treated With Durvalumab After Concurrent Chemoradiation for Unresectable Stage III NSCLC

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 22 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions; Therapeutic Use
Acronyms AYAME
Sponsors AstraZeneca; AstraZeneca KK

Most Recent Events

17 Jan 2024 Status changed from active, no longer recruiting to completed.
13 Jan 2021 Status changed from recruiting to active, no longer recruiting.
19 Aug 2019 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com